Spots Global Cancer Trial Database for metastatic head and neck cancer
Every month we try and update this database with for metastatic head and neck cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | NCT04534205 | Unresectable He... Metastatic Head... Recurrent Head ... | BNT113 Pembrolizumab | 18 Years - | BioNTech SE | |
| Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers | NCT05091190 | Metastatic NSCL... Metastatic Head... | Blood draws | 18 Years - | Hospices Civils de Lyon | |
| A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | NCT02358031 | Recurrent Head ... Metastatic Head... | Pembrolizumab Cisplatin Carboplatin 5-FU Cetuximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma | NCT05980000 | Recurrent Head ... Recurrent Head ... Recurrent Head ... Metastatic Head... Metastatic Head... HNSCC | Ramucirumab Pembrolizumab | 18 Years - | Washington University School of Medicine | |
| Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG) | NCT03146338 | Metastatic Colo... Metastatic Head... | Magnesium-rich ... | 18 Years - | Weprom | |
| A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes | NCT01620242 | Recurrent Head ... Metastatic Head... | Cabazitaxel | 18 Years - | UNICANCER | |
| A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes | NCT01620242 | Recurrent Head ... Metastatic Head... | Cabazitaxel | 18 Years - | UNICANCER | |
| Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG) | NCT03146338 | Metastatic Colo... Metastatic Head... | Magnesium-rich ... | 18 Years - | Weprom | |
| Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC | NCT04260126 | Metastatic Head... Recurrent Head ... HPV Positive Or... Neoplasms, Head... | Pembrolizumab (... | 18 Years - | PDS Biotechnology Corp. | |
| Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer | NCT03937141 | Metastatic Head... Recurrent Head ... | ADU-S100 | 18 Years - | Chinook Therapeutics, Inc. | |
| Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers | NCT05091190 | Metastatic NSCL... Metastatic Head... | Blood draws | 18 Years - | Hospices Civils de Lyon | |
| BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | NCT04969861 | Metastatic Head... Recurrent Head ... | Bempegaldesleuk... Pembrolizumab | 18 Years - | Nektar Therapeutics | |
| PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | NCT06239220 | Head and Neck C... Head and Neck S... Metastatic Head... Recurrent Head ... Metastatic Head... Recurrent Head ... | PD-L1 t-haNK Cetuximab N-803 | 18 Years - | Dana-Farber Cancer Institute | |
| Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG) | NCT03146338 | Metastatic Colo... Metastatic Head... | Magnesium-rich ... | 18 Years - | Weprom | |
| BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | NCT04969861 | Metastatic Head... Recurrent Head ... | Bempegaldesleuk... Pembrolizumab | 18 Years - | Nektar Therapeutics | |
| Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC | NCT05057247 | Squamous Cell C... Recurrent Squam... Metastatic Head... Advanced Head a... Advanced Head a... | Duvelisib Docetaxel | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers | NCT04902027 | Recurrent Head ... Metastatic Head... | Mitoxantrone Hy... | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer | NCT00088907 | Recurrent Head ... Metastatic Head... | docetaxel placebo gefitinib | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
